SCHEMBL6701833

SCHEMBL6701833

C(#Cc1cccs1)COCCn1cnc2cnc3ccccc3c21

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 2/20 0.38
KMT2A Q03164 3/20 0.36
GAA P10253 2/20 0.35
POLB P06746 3/20 0.34
MEN1 O00255 2/20 0.34
HTT P42858 2/20 0.34
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GRM4 Q14833 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6700398 0.82 TLR7 (0.47) SMN1; SMN2LMNAPOLB
SCHEMBL6107128 0.79 SMN1; SMN2 (0.45) SMN1; SMN2LMNAKMT2AGAAPOLB
SCHEMBL6700242 0.77 LMNA (0.41) SMN1; SMN2LMNAKMT2AGAAPOLB
SCHEMBL6729502 0.76 SMN1; SMN2 (0.37) SMN1; SMN2LMNAKMT2APOLBMEN1
SCHEMBL6699766 0.73 SMN1; SMN2 (0.46) SMN1; SMN2LMNAKMT2AGAAPOLB
SCHEMBL15924842 0.70 LMNA (0.46) SMN1; SMN2LMNAKMT2APOLBMEN1
SCHEMBL7103424 0.70 SMN1; SMN2 (0.40) SMN1; SMN2LMNAKMT2APOLBMEN1
SCHEMBL6700111 0.70 MAPK1 (0.40) SMN1; SMN2LMNAKMT2AGAAPOLB
SCHEMBL1893306 0.70 KMT2A (0.47) SMN1; SMN2LMNAKMT2AGAAPOLB
SCHEMBL6105625 0.69 SMN1; SMN2 (0.40) SMN1; SMN2LMNAKMT2AGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US disclosed
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 SMN1; SMN2 4312/4885LMNA 3958/4885KMT2A 808/4885
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 SMN1; SMN2 4312/4885LMNA 3958/4885KMT2A 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.